ApoPharma's President Dr. Michael Spino and Vice President of Medical Affairs Dr. Fernando Tricta were proud to be honoured by the Thalassemia Foundation of Canada (TFC) at its Diamond Year Valentine's Dinner Dance on February 23, 2019.
(Photo L-R, Bessie Calabria, VP, TFC, Dr. Michael Spino, Helen Ziavras, Dr. Fernando Tricta, and Silvia Livia, Board Member TFC)
Dr. Michael Spino, President of ApoPharma and Dr. Fernando Tricta, Vice President of ApoPharma Medical Affairs were honoured among other patient advocates and leaders in thalassaemia care by the United Kingdom Thalassaemia Society (UKTS) at a celebration of the Society's 40th Anniversary in London on October 6, 2018. The Society commended Dr. Spino and Tricta for their leadership in developing Ferriprox, the first oral iron chelator in Europe and a life-saving treatment option. The UKTS funded early studies of deferiprone, recognized its potential and were supporters of efforts to gain European regulatory approval of Ferriprox in 1999. To view a congratulatory video message from ApoPharma to the UKTS, click the link below.
June 8, 2017: Two Toronto scientists who spearheaded the research that brought a life-saving drug to patients around the world will jointly receive the Humanitarian of the Year Award for their work on deferiprone (Ferriprox®), as well as on patient education and empowerment initiatives.
For more information, please visit: www.thalassemia.org
ApoPharma is proud to support the ironwarriors.com website, now available in Arabic, Chinese, English, Portuguese and Turkish. The site was launched in the U.S. and Indonesia in 2017 as a resource for patients and their families.
For more information, please visit: www.ironwarriors.com
Two ApoPharma-sponsored studies in patients with a rare disorder involving brain iron overload were recently concluded. Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of rare inherited movement disorders that usually begin in childhood, are relentlessly progressive, and cause severe disability, eventually leading to premature death. The most common NBIA disorder is pantothenate kinase-associated neurodegeneration (PKAN). TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration) is a research consortium comprising 13 partners from 8 countries and funded by the EU. Along with members of this consortium, the two ApoPharma sponsored studies were looking at the effect of deferiprone in patients with PKAN. These studies were conducted from 2011 to 2017, and reports are now being prepared for publication. Through a compassionate-use program, ApoPharma is continuing to provide deferiprone at no cost to patients who completed the studies.
For more information, please visit: www.tircon.eu